US FDA approves BioCryst's iv flu treatment
This article was originally published in Scrip
Executive Summary
The US FDA has approved BioCryst Pharmaceuticals' flu treatment (peramivir injection) for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The company plans to make it available for the 2014-15 flu season.